186 related articles for article (PubMed ID: 17192125)
21. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats.
Igase M; Strawn WB; Gallagher PE; Geary RL; Ferrario CM
Am J Physiol Heart Circ Physiol; 2005 Sep; 289(3):H1013-9. PubMed ID: 15833808
[TBL] [Abstract][Full Text] [Related]
22. Effects of olmesartan medoxomil as an angiotensin II-receptor blocker in chronic hypoxic rats.
Nakamoto T; Harasawa H; Akimoto K; Hirata H; Kaneko H; Kaneko N; Sorimachi K
Eur J Pharmacol; 2005 Dec; 528(1-3):43-51. PubMed ID: 16336959
[TBL] [Abstract][Full Text] [Related]
23. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
24. Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Kato M; Sada T; Mizuno M; Kitayama K; Inaba T; Koike H
J Cardiovasc Pharmacol; 2005 Oct; 46(4):556-62. PubMed ID: 16160612
[TBL] [Abstract][Full Text] [Related]
25. Essential role of vascular endothelial growth factor in angiotensin II-induced vascular inflammation and remodeling.
Zhao Q; Ishibashi M; Hiasa K; Tan C; Takeshita A; Egashira K
Hypertension; 2004 Sep; 44(3):264-70. PubMed ID: 15262905
[TBL] [Abstract][Full Text] [Related]
26. The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics.
Smith RD; Yokoyama H; Averill DB; Cooke L; Brosnihan KB; Schiffrin EL; Ferrario CM
Am J Cardiovasc Drugs; 2006; 6(5):335-42. PubMed ID: 17083268
[TBL] [Abstract][Full Text] [Related]
27. Olmesartan medoxomil reverses left ventricle hypertrophy and reduces inflammatory cytokine IL-6 in the renovascular hypertensive rats.
Li ZC; Yu HY; Wang XX; Zhang M; Wang JP
Eur Rev Med Pharmacol Sci; 2013 Dec; 17(24):3318-22. PubMed ID: 24379062
[TBL] [Abstract][Full Text] [Related]
28. An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells.
Kurikawa N; Suga M; Kuroda S; Yamada K; Ishikawa H
Br J Pharmacol; 2003 Jul; 139(6):1085-94. PubMed ID: 12871826
[TBL] [Abstract][Full Text] [Related]
29. Olmesartan inhibits the expression of monocyte chemoattractant protein-1 and tumor necrosis factor-alpha and improves vascular remodeling after vascular injury in mouse.
Li Z; Chen XD; Ni SK; Li JW; Lin MS
Chin J Traumatol; 2004 Feb; 7(1):56-61. PubMed ID: 14728822
[TBL] [Abstract][Full Text] [Related]
30. Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
Igase M; Yokoyama H; Ferrario CM
Ther Adv Cardiovasc Dis; 2011 Dec; 5(6):297-304. PubMed ID: 22089474
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
Koike H; Sada T; Mizuno M
J Hypertens Suppl; 2001 Jun; 19(1):S3-14. PubMed ID: 11451212
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin II receptor blocker and statins lower elevated levels of osteopontin in essential hypertension--results from the EUTOPIA trial.
Lorenzen JM; Neunhöffer H; David S; Kielstein JT; Haller H; Fliser D
Atherosclerosis; 2010 Mar; 209(1):184-8. PubMed ID: 19801149
[TBL] [Abstract][Full Text] [Related]
33. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
Smith DH; Dubiel R; Jones M
Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
[TBL] [Abstract][Full Text] [Related]
34. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.
Shimada K; Murayama T; Yokode M; Kita T; Fujita M; Kishimoto C
Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):672-8. PubMed ID: 20399087
[TBL] [Abstract][Full Text] [Related]
35. Severity of hyperlipidemia does not affect antiatherosclerotic effect of an angiotensin II receptor antagonist in apolipoprotein E-deficient mice.
Kato M; Sada T; Chuma H; Mizuno M; Terashima H; Fukushima Y; Koike H
J Cardiovasc Pharmacol; 2006 Jun; 47(6):764-9. PubMed ID: 16810077
[TBL] [Abstract][Full Text] [Related]
36. Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists.
Smith DH
Am J Cardiovasc Drugs; 2007; 7(5):347-56. PubMed ID: 17953473
[TBL] [Abstract][Full Text] [Related]
37. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects.
Kurita S; Takamura T; Ota T; Matsuzawa-Nagata N; Kita Y; Uno M; Nabemoto S; Ishikura K; Misu H; Ando H; Zen Y; Nakanuma Y; Kaneko S
Eur J Pharmacol; 2008 Jul; 588(2-3):316-24. PubMed ID: 18501344
[TBL] [Abstract][Full Text] [Related]
38. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of renin-angiotensin system and oxidative stress.
Suda O; Tsutsui M; Morishita T; Tasaki H; Ueno S; Nakata S; Tsujimoto T; Toyohira Y; Hayashida Y; Sasaguri Y; Ueta Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1682-8. PubMed ID: 15217805
[TBL] [Abstract][Full Text] [Related]
39. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
[TBL] [Abstract][Full Text] [Related]
40. Possible beneficial effect of olmesartan medoxomil on left atrial function in patients with hypertension : noninvasive assessment by acoustic quantification.
Gong HP; Zhang W; Li L; Tan HW; Ma ZY; Zhong XZ; Wang ZH; Song T; Zhang Y; Zhong M
Clin Drug Investig; 2008; 28(4):241-9. PubMed ID: 18345714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
